



HAL
open science

The L,D-transpeptidation pathway is inhibited by antibiotics of the β -lactam class in *Clostridioides difficile*

Ana M Oliveira Paiva, Pascal Courtin, Glenn Charpentier, Olga Soutourina, Marie-Pierre Chapot-Chartier, Johann Peltier

► To cite this version:

Ana M Oliveira Paiva, Pascal Courtin, Glenn Charpentier, Olga Soutourina, Marie-Pierre Chapot-Chartier, et al.. The L,D-transpeptidation pathway is inhibited by antibiotics of the β -lactam class in *Clostridioides difficile*. 2025. hal-04862974

HAL Id: hal-04862974

<https://hal.science/hal-04862974v1>

Preprint submitted on 3 Jan 2025

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **The L,D-transpeptidation pathway is inhibited by antibiotics of the β -lactam class in**
2 ***Clostridioides difficile***

3

4

5

6 Ana M. Oliveira Paiva¹, Pascal Courtin², Glenn Charpentier¹, Olga Soutourina¹, Marie-Pierre
7 Chapot-Chartier², Johann Peltier^{1,3*}

8

9 ¹Université Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC),
10 Gif-sur-Yvette, France.

11 ²Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, Jouy-en-Josas, France.

12 ³Lead contact.

13

14 * Correspondance: johann.peltier@i2bc.paris-saclay.fr

15

16

17 ORCID: AMOP: 0000-0002-6122-832X; MPCC: 0000-0002-4947-0519; OS: 0000-0001-
18 6439-7228; JP: 0000-0003-3207-9465

19

20

21

22 **Summary**

23 The resistance of *Clostridioides difficile* to the β -lactam antibiotics cephalosporins, which
24 target the peptidoglycan (PG) assembly, is a leading contributor to the development of *C.*
25 *difficile* infections. *C. difficile* has an original PG structure with a predominance of 3→3 cross-
26 links generated by L,D-transpeptidases (LDTs). *C. difficile* forms spores and we show that the
27 spore cortex PG contains exclusively 3→3 cross-links. PG and spore cortex of *C. difficile* cells
28 were largely unaffected by the deletion of the three predicted LDTs, revealing the implication
29 of a new family of LDTs. The D,D-carboxypeptidases producing the essential LDT substrate
30 were inactivated by cephalosporins, resulting in the inhibition of the L,D-transpeptidation
31 pathway. In contrast, the participation of penicillin-binding proteins (PBPs) to PG cross-linking
32 increased in the presence of the antibiotics. Our findings highlight that cephalosporin resistance
33 is not primarily mediated by LDTs and illustrate the plasticity of the PG biosynthesis
34 machinery in *C. difficile*.

35

36 **Keywords:** Bacteria, enzyme catalysis, gene knockout, L,D-Transpeptidases, 3→3 crosslink,
37 peptidoglycan, spores, antibiotic resistance, *Clostridioides difficile*

38

39 **Introduction**

40 *Clostridioides difficile* is the primary cause of antibiotic-associated nosocomial diarrhea in
41 adults¹. *C. difficile* forms spores that are essential for the dissemination of *C. difficile* infections
42 (CDI)². Antibiotic exposure resulting in gastrointestinal dysbiosis is commonly associated
43 with the development of CDI¹. β -lactam antibiotics, particularly cephalosporins, are widely
44 recognized as key factors in the development of CDI. However, the mechanism underlying the
45 intrinsic resistance of *C. difficile* to these antibiotics remains poorly understood^{3,4}. β -lactams
46 target the cell wall peptidoglycan (PG) assembly. PG is a polymeric macromolecule consisting

47 of linear glycan chains cross-linked by short peptides⁵. The D,D-transpeptidase (DDT) activity
48 of penicillin-binding proteins (PBPs) connects the fourth amino acid of one peptide side chain
49 to the third amino acid of another, forming 4→3 cross-links. However, 3→3 cross-links
50 generated by L,D-transpeptidases (LDTs) presenting a YkuD-like domain have also been
51 reported⁶. In addition to their cross-linking activity, both DDTs and LDTs catalyze exchange
52 reactions where the terminal D-Ala in pentapeptides and tetrapeptides, respectively, are
53 replaced by a non-canonical D-amino acid (NCDAA)^{7,8}. DDTs, which are the primary targets
54 of β-lactam antibiotics, use native PG precursors containing a pentapeptide stem as acyl donors
55 for cross-linking. In contrast, LDT activity requires a tetrapeptide stem as the acyl donor
56 substrate⁶. This substrate is typically produced by D,D-carboxypeptidases that cleave the fifth
57 residue from the pentapeptide chain⁹⁻¹¹. LDTs have the potential to confer resistance to β-
58 lactam antibiotics, as they are solely inhibited by β-lactam antibiotics of the carbapenem class
59¹².

60 *C. difficile* is the only known Bacillota with predominant 3→3 PG cross-links^{6,13,14}. Recent
61 studies revealed that a mutant strain of *C. difficile* R20291, which lacks all three LDT
62 paralogues, is not impaired in the production of 3→3 cross-links^{15,16}. Furthermore, two new
63 enzymes with a VanW catalytic domain have been identified as the missing LDTs¹⁶. However,
64 the role of 3→3 cross-linking in mediating cephalosporin resistance in *C. difficile* remains
65 unclear. While the structure of the *C. difficile* spore cortex, a modified layer of PG, has also
66 been characterized, the type of cross-links present has not been defined¹⁷.

67 In this study, we showed that the spore cortex PG of *C. difficile* only contains 3→3 cross-links.
68 As for the PG of vegetative cells, 3→3 cross-links were still present in the spore cortex of a *C.*
69 *difficile* strain lacking the three YkuD domain-containing LDTs, suggesting the implication of
70 the VanW domain proteins. By treating *C. difficile* cells with subinhibitory concentrations of

71 β -lactams, including cephalosporins and carbapenems, we discovered that at least one D,D-
72 carboxypeptidase, which is necessary for the production of LDT substrates, is the primary
73 target of these antibiotics and is differentially sensitive to them. In contrast, PBPs generating
74 the 4 \rightarrow 3 cross-links are not inhibited by these concentrations of antibiotics. Thus,
75 cephalosporin resistance in *C. difficile* is not dependent on PG cross-linking by LDTs and
76 instead relies on the poor inhibition of PBPs by this antibiotic family. These findings suggest
77 that the growth arrest induced by β -lactams is mediated by the inhibition of the L,D-
78 transpeptidation pathway in *C. difficile*.

79 **Results**

80 **A strain lacking the three YkuD proteins still predominantly produces 3 \rightarrow 3 cross-links.**

81 To evaluate the role of the three proteins harboring the catalytic domain YkuD on the PG
82 structure of *C. difficile* 630 Δ *erm*, we generated a triple mutant of the corresponding genes *ldt*_{*cd1*}
83 (*CD2963*), *ldt*_{*cd2*} (*CD2713*) and *ldt*_{*cd3*} (*CD3007*)¹⁴ (Figures S1A and S1B). This mutant, hereby
84 referred as $\Delta\Delta\Delta$ *ldt*, was confirmed via whole-genome sequencing and no additional mutation
85 could be detected (see STAR methods). The growth rate of the $\Delta\Delta\Delta$ *ldt* strain was similar to
86 that of the parental strain 630 Δ *erm* (Figure S1C).

87 Wild-type and $\Delta\Delta\Delta$ *ldt* cells were collected in exponential growth and the purified PG was
88 digested with mutanolysin to generate muropeptides. Muropeptides were analyzed by ultra-
89 high performance liquid chromatography coupled to tandem mass spectrometry (UHPLC-
90 MS/MS) (Figure 1A) and their structure was deduced from their *m/z* values and fragmentation
91 patterns obtained by MS/MS. The structure of all identified muropeptides is summarized in
92 Table S1. The muropeptide composition of the $\Delta\Delta\Delta$ *ldt* strain was largely similar to that of the
93 parental strain (Figure 1A and Table S1). The main difference was a strong reduction of the
94 abundance of muropeptides containing a tetrapeptide stem ending in Gly (peaks 4 and 11) in

95 the mutant compared to the wild-type strain (Figures 1A and 1C and Table S1), revealing a
96 role of at least one of the three enzymes in the exchange reaction of the terminal D-Ala in
97 tetrapeptide stems with Gly. Additionally, a small but significant decrease of the dimers cross-
98 linked by L,D-transpeptidation, which results in a reduction of the cross-linking index was
99 observed in the $\Delta\Delta\Delta ldt$ strain compared to the parental strain (Figures 1C and 1D).
100 Nonetheless, 3→3 cross-links remained predominant in the triple mutant strain, indicating the
101 presence of LDTs with a different catalytic domain compensating for the loss of the canonical
102 LDTs.

103 To confirm the impact of the mutations on the exchange reaction, *C. difficile* cells were labeled
104 with the amino-acid probe HCC-amino D-alanine (HADA)^{18,19} during exponential growth and
105 visualized using fluorescence microscopy (Figure S2A). The cell length and width between the
106 triple mutant and the parental strain were identical (Figures S2B and S2C). In pre-divisional
107 cells, the intensity of the HADA staining significantly increased at mid-cell, as expected for
108 the septum formation (Figures S2A, S2D and S2E). In dividing cells, a gradient of fluorescence
109 was observed with a concentrated signal at one of the poles, which presumably corresponds to
110 the newly formed pole, and a fading signal at the other pole (Figures S2A and S2E). The triple
111 mutant showed a similar fluorescent labelling profile to the wild type around the cells, but an
112 overall significant decrease in fluorescence intensity (Figures S2A and S2D). This result
113 suggests that HADA incorporation through the exchange reaction into the PG of *C. difficile* is
114 partially dependent on the activity of at least one of the LDTs.

115 **Ldt_{Ca1} contributes to the exchange reaction and the generation of 3→3 cross-links.** To
116 elucidate the contribution of the three LDTs to exchange reactions and 3→3 crosslinking, the
117 muropeptide profile of the different single and double mutants was also analyzed (Figure S3
118 and Table S1). The abundance of tetrapeptides ending in Gly and of 3→3 cross-links in the

119 strains deleted of *ldt_{cd2}* and/or *ldt_{cd3}* were similar to those of wild type (Figures 1B and 1C).
120 However, deletion of either *ldt_{cd1}*, *ldt_{cd1}* and *ldt_{cd2}* or *ldt_{cd1}* and *ldt_{cd3}* recapitulated the decrease
121 of tetrapeptides ending in Gly observed in the $\Delta\Delta\Delta ldt$ strain. The proportion of 3→3 cross-
122 links was also reduced in the $\Delta ldt_{cd1}\Delta ldt_{cd2}$ and $\Delta ldt_{cd1}\Delta ldt_{cd3}$ double mutants with an impact
123 on the cross-linking index (Figures 1C and 1D). Thus, these data indicate that the PG
124 modifications observed in the triple mutant strain are mostly mediated by the *ldt_{cd1}* deletion.

125 **The spore cortex of *C. difficile* is cross-linked by L,D-transpeptidation.** To determine the
126 mode of cross-linking in the spore cortex, spores of *C. difficile* 630 Δerm wild type were
127 purified and their PG cortex was isolated. Muropeptides were generated using mutanolysin,
128 analyzed by UHPLC-MS/MS (Figure 2A), and their structure was deduced from their *m/z*
129 values and fragmentation patterns obtained by MS/MS. All the identified peaks are summarized
130 in Table S2. In agreement with a previous report¹⁷, 39.5% ± 3.7% of the NAG residues were
131 found to be *N*-deacetylated in the spore cortex of *C. difficile* wild type (Figure 2B). In addition,
132 31.1 ± 2.9% of the NAM residues were converted to the spore-specific MAL in *C. difficile*
133 spore cortex (Figure 2C). This modification prevents the cleavage between the NAM and NAG
134 residues by mutanolysin, leading to the presence of oligosaccharides among the generated
135 muropeptides. Most of the muropeptides still containing an unmodified NAM residue lacked
136 any stem peptide (34.7 ± 3.1%) or harbored a tetrapeptide stem (30.6 ± 4.6%) (Figure 2C).

137 Among the identified muropeptides, only two corresponded to dimers and no trimer was
138 detected (Table S2). Thus, the spore cortex of *C. difficile* is very weakly cross-linked with a
139 cross-linking index of 1.5 ± 0.3% (Figure 2C). The two dimers had the same structure with a
140 tripeptide and a tetrapeptide stem and both contained a 3→3 cross-link as revealed by the loss
141 of one C-terminal alanine (mass loss of 89.048 Da) from the acceptor tetrapeptide stem in their

142 MS-MS fragmentation spectrum (Figures 3 and S4). Thus, the spore cortex of *C. difficile*
143 contains only 3→3 cross-links.

144 Next, we analyzed the spore PG structure of the $\Delta\Delta\Delta ldt$ strain to assess the implication of the
145 LDTs in the formation of the 3→3 cross-links. However, the muropeptide profile of the mutant
146 was identical to that of the wild-type strain and no decrease of the 3→3 cross-links was
147 observed (Figure 2 and Table S2). These data indicate that either the canonical LDTs do not
148 contribute to the cross-linking of the spore cortex or their loss is compensated by the activity
149 of at least one of the two novel LDTs with a VanW domain¹⁶.

150 **The YkuD domain proteins do not contribute to β -lactam resistance in *C. difficile*.**

151 We investigated the effect of the triple *ldt* deletion on β -lactam resistance in *C. difficile*. Loss
152 of the three L,D-transpeptidases did not alter the minimum inhibitory concentration (MIC) of
153 different members of the β -lactam antibiotics class (Table S3). In addition, growth of the
154 $\Delta\Delta\Delta ldt$ and the parental strains in the presence of subinhibitory concentrations of different β -
155 lactams (1/2 MIC) were similar (Figure S5). We reasoned that the gene expression of the VanW
156 domain LDTs or other enzymes of the PG polymerisation machinery might be induced in the
157 presence of β -lactams to compensate for the loss of the three YkuD proteins. To test this
158 hypothesis, $630\Delta erm$ and $\Delta\Delta\Delta ldt$ were grown in the presence of subinhibitory concentrations
159 of the cephalosporin antibiotic ceftriaxone (1/2 MIC) and the samples were subjected to RNA-
160 sequencing. Whereas genes involved in stress response, such as type I toxin-antitoxin systems
161 were induced in $\Delta\Delta\Delta ldt$, no gene related to PG metabolism, including the VanW proteins
162 (*CD1436* and *CD2149* in $630\Delta erm$) or encoding PG-associated proteins could be identified as
163 differently expressed (Table S4). These data indicate that the YkuD domain proteins are
164 dispensable for β -lactam resistance in *C. difficile* $630\Delta erm$.

165 **The L_D-transpeptidation pathway is inhibited by subinhibitory concentrations of**
166 **cephalosporin and carbapenem antibiotics in *C. difficile***

167 To examine the impact of β -lactams on PG cross-linking, the PG structure of vegetative cells
168 of the $\Delta\Delta\Delta ldt$ strain grown in the presence of 1/2 MIC of the cephalosporin cefoxitin was
169 analysed. *C. difficile* exposure to this antibiotic led to drastic PG structure modifications, in
170 comparison to the non-treated strain, with the appearance of new abundant muropeptides with
171 a pentapeptide stem to the detriment of tetrapeptide stems (Figures 1A, 4A and 4B and Table
172 S1). Muropeptides with a pentapeptide stem accounted for $31.6 \pm 2.4\%$ of the total
173 muropeptides in the cefoxitin-treated strain when they represented only $0.5 \pm 0.04\%$ in the
174 untreated strain. Conversely, the abundance of tetrapeptides decreased from $70.5 \pm 0.9\%$ to
175 $36.6 \pm 0.7\%$ in the presence of the antibiotic (Figure 4B). These changes were accompanied by
176 a 50% decrease of the abundance of muropeptide dimers containing 3 \rightarrow 3 cross-links (Figure
177 4C and Table S1). Remarkably, the cross-linking index remained similar in the absence and in
178 the presence of antibiotics as the 3 \rightarrow 3 cross-link reduction was compensated by an equivalent
179 increase of the 4 \rightarrow 3 cross-linked dimers (Figure 4B). Treatment with ceftriaxone, another
180 antibiotic of the cephalosporin class, resulted in similar PG modifications, although at a lesser
181 extent (Figure S6). Thus, these data strongly suggest that cephalosporins inactivate at high
182 concentrations one or several D,D-carboxypeptidase(s), whose activity is required to produce
183 the substrate of the LDT. They also reveal that at least one PBP catalysing the formation of the
184 4 \rightarrow 3 cross-linking reaction is not inactivated by these antibiotics.

185 *C. difficile* 630 Δerm is resistant to most cephalosporins but susceptible to carbapenems (Table
186 S3)²⁰. To assess whether carbapenems also impacted the activity of D,D-carboxypeptidases in
187 *C. difficile*, PG structure of $\Delta\Delta\Delta ldt$ cells treated with 1/2 MIC of meropenem or imipenem was
188 analysed (Figures 1A and S6A and Table S1). As with cephalosporins, both carbapenem

189 antibiotics induced the appearance of several major muropeptides peaks with pentapeptide
190 stems and modified the balance between 4→3 and 3→3 cross-links to the benefits of 4→3
191 cross-links (Figures 4B, 4C, S6B and S6C). Similar results were obtained when analysing the
192 PG structure of the wild-type strain grown in the presence of cefoxitin or meropenem ruling
193 out an impact of the *ldt* deletions on the D,D-carboxypeptidase inactivation (Figures S7A, S7B
194 and S7C).

195 Another remarkable effect of the antibiotic treatments on the PG structure was the presence of
196 a high proportion of muropeptides with a pentapeptide stem ending with a non-canonical
197 amino-acid (NCDAAs: Gly, Phe, Leu or Val) (Table S1, Figures 4D and S7D). The
198 incorporation of NCDAAs into the PG was shown to regulate the cell wall structure in response
199 to environmental stresses in *Vibrio cholerae* and the same mechanism was suggested in *Bacillus*
200 *subtilis*^{8,21}.

201 Altogether, these data strongly suggest that at least one D,D- carboxypeptidase plays a pivotal
202 role in the control of the mode of transpeptidation in *C. difficile*. This D,D- carboxypeptidase is
203 the primary target of antibiotics of the β-lactam family and is differentially susceptible to these
204 antibiotics with an efficient inhibition by low concentrations of carbapenems but only by high
205 concentrations of cephalosporins. The associated reduction of 3→3 cross-linking, resulting
206 from the limited LDT substrate availability, highlights that cephalosporin resistance is not
207 primarily mediated by LDTs in *C. difficile* but rather relies on PBPs resistant to this class of
208 antibiotics.

209 Discussion

210 In agreement with recent studies^{15,16}, we showed here that a *C. difficile* 630Δ*erm* strain lacking
211 the three predicted LDTs presented only a slight reduction of 3→3 cross-links and a decrease
212 in the exchange reaction. The two novel LDTs with a VanW domain most likely compensate

213 for the loss of the other enzymes as recently shown in the strain R20291¹⁶. PG analysis of the
214 different *ldt* single and double mutant strains further identified Ldt_{Cd1} as the enzyme mediating
215 most of the observed changes. This result is contrasting with *in-vitro* assays of the three
216 recombinant LDTs showing that Ldt_{Cd1} is poorly active and has a weak activity in catalysis of
217 the exchange reaction in comparison to Ldt_{Cd2} and Ldt_{Cd3}^{15,22}.

218 We showed the abundant presence of muramic- δ -lactams and *N*-acetylmuramic acids with no
219 peptide stem, which results in a low amount of cross-links, in the spore cortex of *C. difficile*.
220 Furthermore, we discovered that 3→3 cross-links are largely predominant, if not exclusive, in
221 the spore cortex. In *B. subtilis*, the enzymes required for the cross-linking of the spore cortex
222 are produced in the mother cell and their expression is under control of SigE²³, a sporulation-
223 specific sigma factor. Previous transcriptomic analyses identified *ldtCd3* gene as a member of
224 the SigE regulon in *C. difficile*^{24–26}. In addition, Ldt_{Cd3} was shown to display a strong LDT
225 activity *in vitro*^{15,22}. Yet, deletion of the three LDT-encoding genes had no impact on the
226 abundance of the cross-links in the cortex PG, implying the involvement of the non-canonical
227 LDTs. Future work will be required to identify which LDTs contribute to the formation of the
228 spore cortex peptidoglycan.

229 Among the inhibitors of PG polymerisation, β -lactam antibiotics stand out as the most
230 clinically significant. The β -lactam ring found in all β -lactam antibiotics interacts with the
231 essential nucleophilic serine of PBPs, which can display DDT, endopeptidase or D,D-
232 carboxypeptidase activity²⁷. This interaction results in the creation of a stable acyl-enzyme
233 adduct that interferes with catalysis. In contrast, LDTs are slowly acylated by β -lactams of the
234 penicillin and cephalosporin classes and the resulting acyl-enzymes are rapidly hydrolysed²⁸.
235 Thus, LDTs are insensitive to these antibiotics but are still efficiently inactivated by
236 carbapenems^{29,30}. In agreement, activation of the L,D-transpeptidation pathway in

237 *Enterococcus faecium* and *Escherichia coli* conferred broad-spectrum resistance to β -lactams,
238 with the exception of carbapenems^{29,31}. Conversely, we showed that this pathway is inhibited
239 by both cephalosporins and carbapenems in *C. difficile*, revealing that it does not mediate
240 resistance to these drugs. An inhibition of the DDT activity of PBPs could explain the
241 accumulation of mucopeptides with a pentapeptide stem observed in the presence of the
242 antibiotics. However, this hypothesis is not supported by our data as 4 \rightarrow 3 PG cross-links were
243 more abundant in antibiotic-treated cells. In line with this result, biochemical analyses of the
244 purified class A PBP PBP1 and the class B PBP PBP2 of *C. difficile*, which are respectively
245 essential for cross-links synthesis during vegetative cell division and elongation, revealed that
246 both enzymes are insensitive to most cephalosporins and carbapenems^{32,33}. The only other
247 explanation to the observed structural changes is the inhibition of at least one D,D-
248 carboxypeptidase. Activation of the L,D-transpeptidation pathway leading to β -lactam
249 resistance in *E. faecium* and *E. coli* requires the production of a β -lactam-insensitive D,D-
250 carboxypeptidase to generate the tetrapeptide substrate of LDTs^{11,31}. In contrast, production of
251 the essential LDT-tetrapeptide substrate by a β -lactam-sensitive D,D-carboxypeptidase in *C.*
252 *difficile* results in the suppression of LDT activity in the presence of the antibiotics. Altogether,
253 our data support the hypothesis that at least one D,D-carboxypeptidase, controlling substrate
254 availability for LDTs, is the primary target for cephalosporins and carbapenems in *C. difficile*.
255 Since 3 \rightarrow 3 cross-links are essential for viability in this bacterium¹⁶, substrate deprivation for
256 LDTs most likely represents the original mechanism by which cephalosporins and
257 carbapenems impact *C. difficile* survival. Future research will seek to identify the D,D-
258 carboxypeptidase involved, as this enzyme represents an attractive target for the development
259 of new therapies to fight *C. difficile* infections.

260 **Acknowledgments**

261 We are grateful to Alain Guillot (Micalis, INRAE) and François Fenaille (CEA, Université
262 Paris-Saclay) for helpful discussions. We acknowledge ChemSyBio team (Micalis, INRAE,
263 Jouy-en-Josas) for access to LC-MS/MS facilities. The present work has benefited from
264 Imagerie-Gif core facility supported by l'Agence Nationale de la Recherche (ANR-11-EQPX-
265 0029/Morphoscope, ANR-10-INBS-04/FranceBioImaging; ANR-11-IDEX-0003-02/ Saclay
266 Plant Sciences). This work was funded by the French National Research Agency (ANR-20-
267 CE15-0003-DIFFICROSS to Dr. Johann Peltier).

268 **Author contributions**

269 Conceptualization, A.O.P., M-P.C-C. and J.P.; Methodology, A.O.P. and J.P.; Investigation,
270 A.O.P., G.C. and P.C.; Writing-Original Draft, A.O.P. and J.P.; Writing-Review & Editing,
271 A.O.P., O.S., M-P.C-C. and J.P.; Visualization, A.O.P., P.C., M-P.C-C. and J.P. Supervision
272 A.O.P. and J.P.; Funding Acquisition, J.P.

273 **Declaration of interests**

274 The authors declare no competing interests.

275 **Supplemental information titles and legends**

276 Table S1. Excel file containing additional data too large to fit in a pdf, related to Figures 1, 4,
277 S3, S6 and S7.

278 Document S1. Figures S1-S7 and Tables S2-S6.

279

280 **Figure Legends**

281 **Figure 1. Impact of the *ldt* single, double and triple deletions on the PG structure of *C.***
282 ***difficile* vegetative cells.**

283 (A) LC-MS chromatograms of muropeptides from vegetative cells of *C. difficile* 630 Δ *erm*
284 wild-type (WT) and $\Delta\Delta\Delta$ *ldt* strains. Major peaks are labelled with numbers referring to Table

285 S1. See also Table S1 for the structure of all identified muropeptides. Data are representative
286 of three independent experiments.

287 (B) Abundance of muropeptides containing a modified tetrapeptide stem with the LDT-
288 mediated exchange of the terminal D-Ala by a Gly in the PG from *C. difficile* WT and *ldt* mutant
289 strains.

290 (C) Abundance of muropeptide dimers with a 3→3 crosslink relative to the total cross-links in
291 dimers in the PG from *C. difficile* WT and *ldt* mutant strains.

292 (D) Cross-linking index of PG from *C. difficile* WT and *ldt* mutant strains. The cross-linking
293 index was calculated as described by Glauner³⁴.

294 All graphs represent mean ± SD and include individual data points; $n = 3$ independent
295 experiments for WT and $\Delta\Delta\Delta ldt$ and $n = 2$ independent experiments for the other mutant
296 strains. * $P \leq 0.05$ and **** $P \leq 0.0001$ by a one-way ANOVA followed by a Dunnett's multiple
297 comparisons test.

298 **Figure 2. Impact of the *ldt* triple deletion on the PG structure of *C. difficile* spore cortex.**

299 (A) LC-MS chromatograms of muropeptides from the spore cortex of *C. difficile* 630 Δerm
300 wild-type (WT) and $\Delta\Delta\Delta ldt$ strains. Major peaks are labelled with numbers referring to Table
301 S2. See also Table S2 for the structure of all identified muropeptides. Data are representative
302 of three independent experiments.

303 (B) Abundance of NAG deacetylation in the spore cortex from *C. difficile* WT and $\Delta\Delta\Delta ldt$
304 strains.

305 (C) Abundance of MAL and NAM in the spore cortex from *C. difficile* WT and $\Delta\Delta\Delta ldt$ strains.
306 Percentages of unsubstituted NAM (no peptide) and of NAM substituted with a dipeptide, a
307 tripeptide or a tetrapeptide, or involved in cross-linking are represented.

308 All graphs represent mean ± SD and include individual data points; $n = 3$ independent
309 experiments.

310 **Figure 3. MS/MS analysis of the main mucopeptide dimer from the spore cortex of *C.***
311 ***difficile* wild type.**

312 (A) MS/MS analysis of the molecular ion $[M+2H]^{2+}$ ($m/z = 855.887$ with $z=2$) detected in peak
313 14 with a retention time of 7.99 min in Figure 4A and Table S2. Fragments (squared) were
314 detected as $[M+H]^+$ ($z=1$) or $[M+2H]^{2+}$ ($z=2$) adducts. Fragments resulting from loss of a water
315 molecule are not squared. The fragments allowing assignment of the 3-3 cross-links are
316 highlighted in yellow. (B) Structures inferred from the MS/MS analysis are presented. The loss
317 of one alanine from the C-terminal end of different ions (mass loss of 89.048) establishes the
318 presence of a 3→3 crosslink.

319 **Figure 4. Impact of different β -lactam antibiotics on the PG structure of vegetative cells**
320 **of *C. difficile* $\Delta\Delta\Delta ldt$.**

321 (A) LC-MS chromatogram of mucopeptides from vegetative cells of *C. difficile* $\Delta\Delta\Delta ldt$ strain
322 grown in the presence of subinhibitory concentrations of cefoxitin or meropenem. Peak labels
323 refer to Table S1. New major peaks observed in the presence of the antibiotics are labelled with
324 letters. See also Table S1 for the structure of all identified mucopeptides. Data are
325 representative of three independent experiments.

326 (B) Abundance of mucopeptides with a tetrapeptide or a pentapeptide stem and cross-linking
327 index in the PG of *C. difficile* $\Delta\Delta\Delta ldt$ strain grown in the absence of antibiotics (no ATB) or
328 in the presence of cefoxitin or meropenem. Means and SD are shown; $n = 3$ independent
329 experiments. $****P \leq 0.001$ by a two-way ANOVA followed by a Dunnett's multiple
330 comparisons test comparing values with the average value of the no ATB condition.

331 (C) Abundance of mucopeptide dimers with a 3→3 crosslink relative to the total cross-links in
332 dimers in the PG of *C. difficile* $\Delta\Delta\Delta ldt$ strain grown in the absence of antibiotics (no ATB) or
333 in the presence of cefoxitin or meropenem. Means and SD are shown; $n = 3$ independent

334 experiments. **** $P \leq 0.001$ by a one-way ANOVA followed by a Dunnett's multiple
335 comparisons test comparing values with the average value of the no ATB condition.

336 (D) Abundance of muropeptides with a pentapeptide stem ending with a non-canonical D-
337 amino-acid (NCDAA: Gly, Phe, Leu or Val) relative to the total pentapeptide muropeptides in
338 the $\Delta\Delta\Delta ldt$ strain.

339 All graphs represent mean \pm SD and include individual data points; $n = 3$ independent
340 experiments. **** $P \leq 0.001$ by a two-way ANOVA followed by a Dunnett's multiple
341 comparisons test (B and C).

342

343 **STAR Methods**

344 **Resource availability**

345 **Lead contact**

346 Further information and requests for resources and reagents should be directed to and will be
347 fulfilled by the lead contact, Johann Peltier (johann.peltier@i2bc.paris-saclay.fr).

348 **Materials availability**

349 Strains generated in this study are available from the lead contact without restrictions.

350 **Data and code availability**

- 351
- LC-MS/MS datasets have been deposited in the GLYCOPOST repository
352 (GPST000426) and are publicly available as of the date of publication.. RNA-seq and
353 whole genome sequencing data have been deposited to the NCBI Sequence Read
354 Archive (SRA) BioProject PRJNA1107170 and are publicly available as of the date of
355 publication.
 - This paper does not report original code.
- 356

- 357 • Any additional information required to reanalyze the data reported in this paper is
358 available from the lead contact upon request.

359 **Experimental models and study participant details**

360 *Bacterial strains and growth conditions*

361 *C. difficile* strains were grown in an anaerobic Jacomex workstation with an atmosphere of 5%
362 H₂, 5% CO₂ and 90% N₂. *C. difficile* strains were cultured in Brain Heart Infusion broth (BHI,
363 BD Difco) or Sporulation Medium for *Clostridium difficile* (SMC, 9% Bacto peptone, 0.5%
364 proteose peptone, 0.15% Tris base, 0.1% ammonium sulphate). All the *C. difficile* strains are
365 described in Table S5.

366 Plasmids were maintained in *E. coli* strain NEB10 β and transformed using standard procedures
367 ³⁵. *E. coli* HB101 carrying the plasmid RP4 was used for plasmid conjugation with *C. difficile*
368 strains ^{36,37}. The *E. coli* strains were cultured in Luria Bertani broth (LB Lennox, Sigma)
369 supplemented with chloramphenicol at 15 μ g/mL or 100 μ g/mL ampicillin when required, and
370 were grown aerobically at 37°C.

371 The growth was followed by optical density reading at 600 nm. Growth curves were performed
372 in 96-well plates, with a starting culture at a normalized OD₆₀₀ \approx 0.05, under anaerobic
373 conditions at 37 °C, in Stratus Plate Reader (Cerillo). The OD₆₀₀ value for each well was
374 recorded every 30 min.

375 **Method details**

376 *Construction of the C. difficile ldt mutants*

377 All primers used in this study are listed in Table S6. The *C. difficile* *ldt* deletion mutants were
378 created using a toxin-mediated allele exchange method ³⁸. Briefly, \sim 800 bp homology arms
379 flanking the region to be deleted were amplified by PCR from *C. difficile* 630 Δ *erm*. Purified

380 PCR products were cloned into the PmeI site of the pseudo-suicide allele-coupled exchange
381 (ACE) vector pMSR0³⁸ using NEBuilder HiFi DNA Assembly (New England Biolabs). The
382 resulting plasmids, listed in Table S5, were transformed into *E. coli* strain NEB10 β (New
383 England Biolabs) and all inserts were verified by sequencing. Plasmids were then transformed
384 into *E. coli* HB101(RP4) and transferred by conjugation into the appropriate *C. difficile* strains.
385 Transconjugants were selected on BHI supplemented with *Clostridioides difficile* Selective
386 Supplement (CDSS; Oxoid), and 7.5 μ g/mL thiamphenicol. Allelic exchange was performed
387 as described³⁸. All strains were confirmed by locus amplification. The triple mutant was further
388 confirmed by whole-genome sequencing.

389 ***Whole genome sequencing***

390 *C. difficile* strains were grown in BHI for 24h. Cells were harvested and genomic DNA was
391 isolated using NucleoSpin Microbial DNA Mini kit for DNA (Macherey-Nagel). Bacterial
392 genomes were sequenced at Plasmidsaurus (<https://www.plasmidsaurus.com/>) using the long-
393 read sequencing technology from Oxford Nanopore Technologies (ONT). Using Galaxy
394 Europe, quality controls were performed with FastQC and nanoplot and adapter trimming was
395 performed with Porechop. The resulting reads were mapped to the reference genome using
396 Map with minimap2. Small indels (<50 bp) and SNPs were identified using Clair3, bcftools
397 norm and SnpSift Filter. Large indels were identified using CuteSV. Raw sequence files were
398 deposited to the NCBI Sequence Read Archive (SRA) BioProject PRJNA1107170.

399 ***Fluorescence microscopy***

400 The sample preparation for fluorescence microscopy was carried out under anaerobic
401 conditions. *C. difficile* strains were cultured in BHI. When required, 1 mL culture was
402 incubated with HADA at a final concentration of 10 μ M ($\lambda_{em} \approx 450$ nm, Tocris Bioscience)¹⁹
403 for 10 min and washed 3X with anaerobic PBS. Cells were spotted on GeneFrame slides with

404 1.5% agarose patches. Microscopy was carried out with spinning disk confocal microscopy,
405 using an Inverted Eclipse Ti-E (Nikon) equipped with CSU-X1-A1, Nipkow Spinning Disk
406 confocal system (Yokogawa) and ORCA-Flash4.0 LT CMOS camera (Hamamatsu). Data and
407 statistical analysis were done with MicrobeJ version 5.13I plugin for ImageJ^{39,40}. Recognition
408 of cells was limited to 1 μm^2 minimum and 1 - 16 μm length. Cells with defective detection
409 were excluded from analysis. Fluorescent intensity profiles of contour and medial were used
410 for analysis of 2 independent biological replicates. Representative pictures were prepared for
411 publication in CorelDRAW X8 (Corel).

412 ***Spore purification***

413 Overnight cultures of *C. difficile* $\Delta\Delta\Delta/dt$ and parental strains grown in BHI were spread out on
414 twelve SMC agar plates for sporulation⁴¹. After 7 days of anaerobic incubation at 37°C, cells
415 and spores were harvested in 2 ml of ice-cold sterile water. Crude suspensions were washed 10
416 times with ice-cold sterile water and spores were purified with a HistoDenz (Merck) gradient
417 20-50%.

418 ***Purification and structural analysis of PG***

419 Vegetative PG was extracted from *C. difficile* strains as previously described with some
420 modifications¹⁴. *C. difficile* cultures were grown to $\text{OD}_{600} \approx 1.0$ at 37°C in BHI with the
421 addition of cefoxitin (64 $\mu\text{g}/\text{mL}$), ceftriaxone (32 $\mu\text{g}/\text{mL}$), meropenem (1 $\mu\text{g}/\text{mL}$) or imipenem
422 (2 $\mu\text{g}/\text{mL}$), when required. Cells were harvested by centrifugation at 5000g for 10 min and
423 processed in a FastPrep apparatus (MP Bioscience) for 30 s at 4 m/s to break the cells. For
424 spore PG extraction, purified spores were additionally incubated twice in decoating buffer (50
425 mM Tris-HCl pH8.0, 8M Urea, 1% sodium dodecyl sulfate (SDS), 50 mM DTT) for 1h at
426 37°C. Samples were harvested by centrifugation at 17000g for 10 min.

427 Both cell and spore pellets were resuspended in cold H₂O, boiled for 10 min, cooled again, and
428 centrifuged at 17000g for 10 min. The cells were then boiled in 10% SDS, followed by boiling
429 in 4% SDS and washed 10 times with H₂O. The insoluble material was then treated with
430 pronase for 90 min at 60°C, followed by incubation with DNase, RNase, Lipase and trypsin
431 for 20h at 37°C to purify the cell wall. Finally, the samples were incubated in 48% hydrofluoric
432 acid at 4 °C for 16 h to remove wall polysaccharides. Purified PG was digested with
433 mutanolysin (Sigma), and the soluble muropeptides were reduced with sodium borohydride.
434 Muropeptides were analyzed by LC-MS/MS with an UHPLC instrument (Vanquish Flex,
435 Thermo Scientific) connected to a Q-Exactive Focus mass spectrometer (Thermo Fisher
436 Scientific) fitted with an H-ESI electrospray source (facilities located at ChemSyBio, Micalis,
437 INRAE, Jouy-en-Josas). They were separated by reverse phase chromatography with a
438 ZORBAX Eclipse Plus C18 RRHD column (100 by 2.1mm; particle size, and 1.8µm; Agilent
439 Technologies) at 50°C using 10 mM ammonium formate buffer (pH 4.6) and a 20 min linear
440 gradient from 0 to 20% methanol at a flow rate of 0.3 ml/min. Mass analysis was performed in
441 positive mode with an acquisition range of 380 -1400 *m/z* at resolution 17,500. The Q-Exactive
442 mass spectrometer was operated with capillary voltage at 3.5 kV and a capillary temperature
443 set at 320°C. MS2 was performed in an acquisition range of 160-1600 *m/z* with an AGC target
444 at 2.10⁵ with HCD collision anode at energy 25. Data were acquired with the Qual Browser
445 suite (Thermo Xcalibur).

446 Muropeptides were identified from their *m/z* values and MS/MS spectra when required. They
447 were quantified using Skyline open-source software ⁴² following the procedure for small
448 molecule quantification and considering the different adducts and charge states detected for
449 each muropeptide.

450 The cross-linking index (CI) was calculated according to Glauner³⁴ as follows: $CI = (1/2$
451 $\Sigma dimers + 2/3 \Sigma trimers) / \Sigma all\ muropeptides$. The relative amount of muropeptides with a certain

452 side chain (X) with a free terminal carboxyl group (acceptor chain) was calculated according
453 to Glauner³⁴ as follows: percentage (X) = (Σ monomers(X) + 1/2 Σ dimers + 1/3 Σ trimers)/ Σ all
454 muropeptides.

455 ***Minimum inhibitory concentration (MIC) determination***

456 For the determination of the MIC, strains were grown until OD₆₀₀ of 1.0 and inoculated to a
457 starting optical density 0.05 in 200 μ L BHI medium supplemented with the required antibiotic
458 range (amoxicillin, oxacillin, cefoxitine, ceftriaxone, imipenem or meropenem) on 96-well
459 plates. Cultures were incubated at 37°C for 24h. MICs for each strain were determined as the
460 lowest concentration without visible growth, at least in three independent experiments.

461 ***RNA sequencing***

462 For total RNA extraction, *C. difficile* strains were grown in 20 mL BHI medium with 32 μ g/mL
463 ceftriaxone, until an optical density of 1.0. Total RNA was isolated as previously described⁴³.
464 Quantification of the RNA samples was performed using the Qubit™ RNA High Sensitivity
465 (ThermoScientific). Samples were sent for RNA sequencing by Novogene Prokaryotic RNA
466 Sequencing services (Novogene). Analysis of the raw FastQ files was performed with Galaxy
467 Pasteur⁴⁴. Quality control of the raw data was assessed using FastQC and raw data were then
468 subjected to trimming and filtering with AlienTrimmer⁴⁵. Sequencing reads were aligned to *C.*
469 *difficile* strain 630 genome (NC_009089.1) with the Bowtie2 software⁴⁶ using default
470 parameters. SARTools DESeq2 was used to perform normalization and differential analysis
471 using values of the 630 Δ *erm* wild-type strain as a reference for reporting the expression data
472 of the $\Delta\Delta\Delta$ *ldt* strain. Genes were considered differentially expressed if they had a \geq twofold
473 increase or decrease in expression and an adjusted *P* value (*q* value) \leq 0.05. Assignment of the
474 functional orthologues (K number) and KEGG pathway was performed automatically using

475 BlastKOALA ⁴⁷ and was then manually edited. RNA-seq raw sequence reads were deposited
476 to the NCBI Sequence Read Archive (SRA) BioProject PRJNA1107170.

477

478

479

480 References

- 481 1. Smits, W.K., Lyras, D., Lacy, D.B., Wilcox, M.H., and Kuijper, E.J. (2016). *Clostridium difficile*
482 infection. *Nat Rev Dis Primers* 2, 16020. <https://doi.org/10.1038/nrdp.2016.20>.
- 483 2. Paredes-Sabja, D., Shen, A., and Sorg, J.A. (2014). *Clostridium difficile* spore biology:
484 sporulation, germination, and spore structural proteins. *Trends Microbiol* 22, 406–416.
485 <https://doi.org/10.1016/j.tim.2014.04.003>.
- 486 3. Gerding, D.N. (2004). Clindamycin, Cephalosporins, Fluoroquinolones, and *Clostridium difficile*
487 –Associated Diarrhea: This Is an Antimicrobial Resistance Problem. *Clinical Infectious Diseases*
488 38, 646–648. <https://doi.org/10.1086/382084>.
- 489 4. Spigaglia, P. (2016). Recent advances in the understanding of antibiotic resistance in
490 *Clostridium difficile* infection. *Ther Adv Infect Dis* 3, 23–42.
491 <https://doi.org/10.1177/2049936115622891>.
- 492 5. Vollmer, W., Blanot, D., and de Pedro, M.A. (2008). Peptidoglycan structure and architecture.
493 *FEMS Microbiol Rev* 32, 149–167. <https://doi.org/10.1111/j.1574-6976.2007.00094.x>.
- 494 6. Aliashkevich, A., and Cava, F. (2022). LD-transpeptidases: the great unknown among the
495 peptidoglycan cross-linkers. *FEBS J*, 289: 4718-4730. <https://doi.org/10.1111/febs.16066>
- 496 7. Lupoli, T.J., Tsukamoto, H., Doud, E.H., Wang, T.-S.A., Walker, S., and Kahne, D. (2011).
497 Transpeptidase-Mediated Incorporation of D-Amino Acids into Bacterial Peptidoglycan. *J Am*
498 *Chem Soc* 133, 10748–10751. <https://doi.org/10.1021/ja2040656>.
- 499 8. Cava, F., de Pedro, M.A., Lam, H., Davis, B.M., and Waldor, M.K. (2011). Distinct pathways for
500 modification of the bacterial cell wall by non-canonical D -amino acids. *EMBO J* 30, 3442–3453.
501 <https://doi.org/10.1038/emboj.2011.246>.
- 502 9. Vermassen, A., Leroy, S., Talon, R., Provot, C., Popowska, M., and Desvaux, M. (2019). Cell Wall
503 Hydrolases in Bacteria: Insight on the Diversity of Cell Wall Amidases, Glycosidases and
504 Peptidases Toward Peptidoglycan. *Front Microbiol* 10, 331.
505 <https://doi.org/10.3389/fmicb.2019.00331>.
- 506 10. Hugonnet, J.-E., Mengin-Lecreux, D., Monton, A., den Blaauwen, T., Carbonnelle, E., Veckerlé,
507 C., Brun, V., van Nieuwenhze, M., Bouchier, C., Tu, K., et al. (2016). Factors essential for L,D-
508 transpeptidase-mediated peptidoglycan cross-linking and b-lactam resistance in *Escherichia*
509 *coli*. *eLife* 5:e19469. <https://doi.org/10.7554/eLife.19469>
- 510 11. Sacco, E., Hugonnet, J.-E., Josseaume, N., Cremniter, J., Dubost, L., Marie, A., Patin, D., Blanot,
511 D., Rice, L.B., Mainardi, J.-L., et al. (2010). Activation of the L,D-transpeptidation peptidoglycan
512 cross-linking pathway by a metallo-D,D-carboxypeptidase in *Enterococcus faecium*. *Mol*
513 *Microbiol* 75, 874–885. <https://doi.org/10.1111/j.1365-2958.2009.07014.x>.

- 514 12. Mora-Ochomogo, M., and Lohans, C.T. (2021). β -Lactam antibiotic targets and resistance
515 mechanisms: from covalent inhibitors to substrates. *RSC Med Chem* *12*, 1623–1639.
516 <https://doi.org/10.1039/D1MD00200G>.
- 517 13. Bern, M., Beniston, R., and Mesnage, S. (2017). Towards an automated analysis of bacterial
518 peptidoglycan structure. *Anal Bioanal Chem* *409*, 551–560. [https://doi.org/10.1007/s00216-](https://doi.org/10.1007/s00216-016-9857-5)
519 [016-9857-5](https://doi.org/10.1007/s00216-016-9857-5).
- 520 14. Peltier, J., Courtin, P., El Meouche, I., Lemée, L., Chapot-Chartier, M.P., and Pons, J.L. (2011).
521 *Clostridium difficile* has an original peptidoglycan structure with a high level of N-
522 acetylglucosamine deacetylation and mainly 3-3 cross-links. *Journal of Biological Chemistry*
523 *286*, 29053–29062. <https://doi.org/10.1074/jbc.M111.259150>.
- 524 15. Galley, N.F., Greetham, D., Alamán-Zárate, M.G., Williamson, M.P., Evans, C.A., Spittal, W.D.,
525 Buddle, J.E., Freeman, J., Davis, G.L., Dickman, M.J., et al. (2023). *Clostridioides difficile*
526 canonical L,D-transpeptidases catalyse a novel type of peptidoglycan cross-links and are not
527 required for beta-lactam resistance. *Journal of Biological Chemistry*, 105529.
528 <https://doi.org/10.1016/j.jbc.2023.105529>.
- 529 16. Bollinger, K.W., Müh, U., Ocius, K.L., Apostolos, A.J., Pires, M.M., Helm, R.F., Popham, D.L.,
530 Weiss, D.S., and Ellermeier, C.D. (2024). Identification of a new family of peptidoglycan
531 transpeptidases reveals atypical crosslinking is essential for viability in *Clostridioides difficile*.
532 *bioRxiv*. <https://doi.org/10.1101/2024.03.14.584917>.
- 533 17. Coullon, H., Rifflet, A., Wheeler, R., Janoir, C., Boneca, I.G., and Candela, T. (2018). N-
534 Deacetylases required for muramic-lactam production are involved in *Clostridium difficile*
535 sporulation, germination, and heat resistance. *Journal of Biological Chemistry* *293*, 18040–
536 18054. <https://doi.org/10.1074/jbc.RA118.004273>.
- 537 18. Kuru, E., Radkov, A., Meng, X., Egan, A., Alvarez, L., Dowson, A., Booher, G., Breukink, E., Roper,
538 D.I., Cava, F., et al. (2019). Mechanisms of Incorporation for D -Amino Acid Probes That Target
539 Peptidoglycan Biosynthesis. *ACS Chem Biol* *14*, 2745–2756.
540 <https://doi.org/10.1021/acschembio.9b00664>.
- 541 19. Kuru, E., Hughes, H.V., Brown, P.J., Hall, E., Tekkam, S., Cava, F., De Pedro, M.A., Brun, Y. V.,
542 and Vannieuwenhze, M.S. (2012). In situ probing of newly synthesized peptidoglycan in live
543 bacteria with fluorescent D-amino acids. *Angewandte Chemie - International Edition* *51*,
544 12519–12523. <https://doi.org/10.1002/anie.201206749>.
- 545 20. Toth, M., Stewart, N.K., Smith, C., and Vakulenko, S.B. (2018). Intrinsic class d β -lactamases of
546 *Clostridium difficile*. *mBio* *9*. <https://doi.org/10.1128/mBio.01803-18>.
- 547 21. Lam, H., Oh, D.-C., Cava, F., Takacs, C.N., Clardy, J., de Pedro, M.A., and Waldor, M.K. (2009).
548 D-Amino Acids Govern Stationary Phase Cell Wall Remodeling in Bacteria. *Science* (1979) *325*,
549 1552–1555. <https://doi.org/10.1126/science.1178123>.

- 550 22. Sütterlin, L., Edoó, Z., Hugonnet, J.-E., Mainardi, J.-L., and Arthur, M. (2018). Peptidoglycan
551 Cross-Linking Activity of L,D-Transpeptidases from *Clostridium difficile* and Inactivation of
552 These Enzymes by β -Lactams. *Antimicrob Agents Chemother* 62.
553 <https://doi.org/10.1128/AAC.01607-17>.
- 554 23. Popham, D.L., and Bernhards, C.B. (2015). Spore Peptidoglycan. *Microbiol Spectr* 3.
555 <https://doi.org/10.1128/microbiolspec.TBS-0005-2012>.
- 556 24. Fimlaid, K.A., Bond, J.P., Schutz, K.C., Putnam, E.E., Leung, J.M., Lawley, T.D., and Shen, A.
557 (2013). Global Analysis of the Sporulation Pathway of *Clostridium difficile*. *PLoS Genet* 9.
558 <https://doi.org/10.1371/journal.pgen.1003660>.
- 559 25. Saujet, L., Pereira, F.C., Serrano, M., Soutourina, O., Monot, M., Shelyakin, P. V., Gelfand, M.S.,
560 Dupuy, B., Henriques, A.O., and Martin-Verstraete, I. (2013). Genome-Wide Analysis of Cell
561 Type-Specific Gene Transcription during Spore Formation in *Clostridium difficile*. *PLoS Genet* 9.
562 <https://doi.org/10.1371/journal.pgen.1003756>.
- 563 26. Soutourina, O., Dubois, T., Monot, M., Shelyakin, P. V., Saujet, L., Boudry, P., Gelfand, M.S.,
564 Dupuy, B., and Martin-Verstraete, I. (2020). Genome-Wide Transcription Start Site Mapping
565 and Promoter Assignments to a Sigma Factor in the Human Enteropathogen *Clostridioides*
566 *difficile*. *Front Microbiol* 11. <https://doi.org/10.3389/fmicb.2020.01939>.
- 567 27. Sauvage, E., Kerff, F., Terrak, M., Ayala, J.A., and Charlier, P. (2008). The penicillin-binding
568 proteins: Structure and role in peptidoglycan biosynthesis. *FEMS Microbiology Reviews* 32 (2),
569 234–258. <https://doi.org/10.1111/j.1574-6976.2008.00105.x>
- 570 28. Triboulet, S., Dubée, V., Lecoq, L., Bougault, C., Mainardi, J.-L., Rice, L.B., Ethève-Quellejeu,
571 M., Gutmann, L., Marie, A., Dubost, L., et al. (2013). Kinetic features of L,D-transpeptidase
572 inactivation critical for β -lactam antibacterial activity. *PLoS One* 8, e67831.
573 <https://doi.org/10.1371/journal.pone.0067831>.
- 574 29. Mainardi, J.L., Hugonnet, J.E., Rusconi, F., Fourgeaud, M., Dubost, L., Mouti, A.N., Delfosse, V.,
575 Mayer, C., Gutmann, L., Rice, L.B., et al. (2007). Unexpected inhibition of peptidoglycan LD-
576 transpeptidase from *Enterococcus faecium* by the β -lactam imipenem. *Journal of Biological*
577 *Chemistry* 282, 30414–30422. <https://doi.org/10.1074/jbc.M704286200>.
- 578 30. Dubée, V., Arthur, M., Fief, H., Triboulet, S., Mainardi, J.L., Gutmann, L., Sollogoub, M., Rice,
579 L.B., Ethève-Quellejeu, M., and Hugonnet, J.E. (2012). Kinetic analysis of *Enterococcus*
580 *faecium* L,D-transpeptidase inactivation by carbapenems. *Antimicrob Agents Chemother* 56,
581 3409–3412. <https://doi.org/10.1128/AAC.06398-11>.
- 582 31. Hugonnet, J.-E., Mengin-Lecreulx, D., Monton, A., den Blaauwen, T., Carbonnelle, E., Veckerlé,
583 C., Brun, Y. V., van Nieuwenhze, M., Bouchier, C., Tu, K., et al. (2016). Factors essential for L,D-
584 transpeptidase-mediated peptidoglycan cross-linking and β -lactam resistance in *Escherichia*
585 *coli*. *Elife* 5. <https://doi.org/10.7554/eLife.19469>.

- 586 32. Sacco, M.D., Wang, S., Adapa, S.R., Zhang, X., Lewandowski, E.M., Gongora, M. V.,
587 Keramisanou, D., Atlas, Z.D., Townsend, J.A., Gatdula, J.R., et al. (2022). A unique class of Zn²⁺-
588 binding serine-based PBPs underlies cephalosporin resistance and sporogenesis in
589 *Clostridioides difficile*. *Nat Commun* 13. <https://doi.org/10.1038/s41467-022-32086-6>.
- 590 33. Dingle, K.E., Freeman, J., Didelot, X., Quan, T.P., Eyre, D.W., Swann, J., Spittal, W.D., Clark, E.
591 V., Jolley, K.A., Walker, A.S., et al. (2023). Penicillin Binding Protein Substitutions Cooccur with
592 Fluoroquinolone Resistance in Epidemic Lineages of Multidrug-Resistant *Clostridioides difficile*.
593 *mBio* 14. <https://doi.org/10.1128/mbio.00243-23>.
- 594 34. Glauner, B. (1988). Separation and quantification of mucopeptides with high-performance
595 liquid chromatography. *Anal Biochem* 172, 451–464. [https://doi.org/10.1016/0003-
596 2697\(88\)90468-X](https://doi.org/10.1016/0003-2697(88)90468-X).
- 597 35. Tom Maniatis, Joseph Sambrook, and E. F. Fritsch (1989). *Molecular Cloning*. Cold Spring
598 Harbor Laboratory 2 edition.
- 599 36. Hussain, H.A., Roberts, A.P., and Mullany, P. (2005). Generation of an erythromycin-sensitive
600 derivative of *Clostridium difficile* strain 630 (630Δerm) and demonstration that the conjugative
601 transposon Tn916ΔE enters the genome of this strain at multiple sites. *J Med Microbiol* 54,
602 137–141. <https://doi.org/10.1099/jmm.0.45790-0>.
- 603 37. Bouillaut, L., McBride, S.M., and Sorg, J.A. (2011). Genetic Manipulation of *Clostridium difficile*.
604 *Curr Protoc Microbiol* 20. <https://doi.org/10.1002/9780471729259.mc09a02s20>.
- 605 38. Peltier, J., Hamiot, A., Garneau, J.R., Boudry, P., Maikova, A., Hajnsdorf, E., Fortier, L.C., Dupuy,
606 B., and Soutourina, O. (2020). Type I toxin-antitoxin systems contribute to the maintenance of
607 mobile genetic elements in *Clostridioides difficile*. *Commun Biol* 3.
608 <https://doi.org/10.1038/s42003-020-01448-5>.
- 609 39. Rueden, C.T., Schindelin, J., Hiner, M.C., DeZonia, B.E., Walter, A.E., Arena, E.T., and Eliceiri,
610 K.W. (2017). ImageJ2: ImageJ for the next generation of scientific image data. *BMC*
611 *Bioinformatics* 18, 529. <https://doi.org/10.1186/s12859-017-1934-z>.
- 612 40. Ducret, A., Quardokus, E.M., and Brun, Y. V. (2016). MicrobeJ, a tool for high throughput
613 bacterial cell detection and quantitative analysis. *Nat Microbiol* 1, 16077.
614 <https://doi.org/10.1038/nmicrobiol.2016.77>.
- 615 41. Permpoonpattana, P., Tolls, E.H., Nadem, R., Tan, S., Brisson, A., and Cutting, S.M. (2011).
616 Surface Layers of *Clostridium difficile* Endospores. *J Bacteriol* 193, 6461–6470.
617 <https://doi.org/10.1128/JB.05182-11>.
- 618 42. Pino, L.K., Searle, B.C., Bollinger, J.G., Nunn, B., MacLean, B., and MacCoss, M.J. (2020). The
619 Skyline ecosystem: Informatics for quantitative mass spectrometry proteomics. *Mass*
620 *Spectrom Rev* 39, 229–244. <https://doi.org/10.1002/mas.21540>.

- 621 43. Peltier, J., and Soutourina, O. (2017). Identification of c-di-GMP-responsive riboswitches. In
622 Methods in Molecular Biology (Humana Press Inc.), 377–402. [https://doi.org/10.1007/978-1-](https://doi.org/10.1007/978-1-4939-7240-1_29)
623 4939-7240-1_29.
- 624 44. Afgan, E., Nekrutenko, A., Grüning, B.A., Blankenberg, D., Goecks, J., Schatz, M.C., Ostrovsky,
625 A.E., Mahmoud, A., Lonie, A.J., Syme, A., et al. (2022). The Galaxy platform for accessible,
626 reproducible and collaborative biomedical analyses: 2022 update. *Nucleic Acids Res* 50, W345–
627 W351. <https://doi.org/10.1093/nar/gkac247>.
- 628 45. Criscuolo, A., and Brisse, S. (2013). AlienTrimmer: A tool to quickly and accurately trim off
629 multiple short contaminant sequences from high-throughput sequencing reads. *Genomics* 102,
630 500–506. <https://doi.org/10.1016/j.ygeno.2013.07.011>.
- 631 46. Langmead, B., and Salzberg, S.L. (2012). Fast gapped-read alignment with Bowtie 2. *Nat*
632 *Methods* 9, 357–359. <https://doi.org/10.1038/nmeth.1923>.
- 633 47. Kanehisa, M., Sato, Y., and Morishima, K. (2016). BlastKOALA and GhostKOALA: KEGG Tools for
634 Functional Characterization of Genome and Metagenome Sequences. *J Mol Biol* 428, 726–731.
635 <https://doi.org/10.1016/j.jmb.2015.11.006>.
- 636
- 637

Figure 1









Figure 2

Figure 3

A



B








Figure 4








Figure S1 - Impact of a triple mutant of the LDT-encoding genes on *C. difficile* growth.

(A) Domain composition of the L.D-transpeptidases Ldt_{Cd1} (CD2963), Ldt_{Cd2} (CD2713) and Ldt_{Cd3} (CD3007) from *C. difficile*. The different conserved domains are represented: transmembrane region (TM in grey), peptidoglycan and cell-wall binding domain (PG_b4 and CW_b2, in light grey), LDT catalytic domain (YkuD in dark grey), cholin-binding domain (CB in stripes) and the SH3 domain associated with a variety of intracellular or membrane-associated proteins (dots).

(B) PCR amplification from *C. difficile* 630 Δ erm wild-type (WT), $\Delta\Delta\Delta$ ldt, Δ ldt_{Cd1}, Δ ldt_{Cd2}, Δ ldt_{Cd3}, Δ ldt_{Cd1} Δ ldt_{Cd2}, Δ ldt_{Cd1} Δ ldt_{Cd3} and Δ ldt_{Cd2} Δ ldt_{Cd3, with specific primers to the locus region of ldt_{Cd1}, ldt_{Cd2} and ldt_{Cd3} to verify the different alleles. **C.** Growth curves of *C. difficile* WT and $\Delta\Delta\Delta$ ldt strains in BHI medium. Means and SD are shown; n = 3 independent experiments.}




Fig. S2. Analysis of cell morphology and HADA incorporation in *C. difficile* 630 Δerm and $\Delta\Delta\Delta\text{ldt}$.

(A) Cells were collected at an $\text{OD}_{600\text{nm}}$ of 0.6 and stained with the fluorescent D-amino-acid HADA for 10 min. Cells were imaged on the green channel for the autofluorescence (excitation, 488nm) and on the blue channel for HADA (excitation, 405nm). Scalebar=3 μm . Pictures were treated equally and are representative of 3 independent experiments.

(B) Scatter plot showing cell length of 630 Δerm and $\Delta\Delta\Delta\text{ldt}$ strains with the median of each distribution indicated by a black line.

(C) Scatter plot showing cell width of 630 Δerm and $\Delta\Delta\Delta\text{ldt}$ strains with the median of each distribution indicated by a black line.

(D) Average contour fluorescence intensity (HADA distribution). Standard deviation is represented by dashed lines.

(E) Analysis of contour fluorescence intensity (HADA distribution) in *C. difficile* 630 Δerm cells. Cells were grouped by fluorescent distribution and pre-divisive cells were identified. Pole 1 and 2, as well as mid-cell are shown. Scale of fluorescent intensity is depicted.

For panels (B) to (E), 2 independent experiments were analysed for *C. difficile* 630 Δerm (grey, $n=544$) and $\Delta\Delta\Delta\text{ldt}$ (orange, $n=878$).




Figure S3 - Impact of *ldt* single and double mutants on the PG structure of *C. difficile* vegetative cells. LC-MS separation of muropeptides from vegetative cells of *C. difficile* Δldt_{cd1} , Δldt_{cd2} , Δldt_{cd3} , $\Delta ldt_{cd1}\Delta ldt_{cd2}$, $\Delta ldt_{cd1}\Delta ldt_{cd3}$ and $\Delta ldt_{cd2}\Delta ldt_{cd3}$ strains. See also Table S1 for the structure of all identified muropeptides. Data are representative of two independent experiments.




Figure S4: MS/MS analysis of the second mucopeptide dimer from the spore cortex of *C. difficile* wild type.

(A) MS/MS analysis of the ion ($m/z = 855.883$ with $z=2$) corresponding to the peak with a retention time of 8.75 min in Fig. 4A and Table S2. Fragments (squared) were detected as $[M+H]^+$ ($z=1$) or $[M+2H]^{2+}$ ($z=2$) adducts. Fragments resulting from loss of a water molecule are not squared. In yellow, the fragments allowing the assignment of the 3-3 cross-link.

(B) Structures inferred from the MS/MS analysis are presented. The loss of one alanine from the C-terminal end of different ions (mass loss of 89.048) establishes the presence of a 3→3 crosslink.




Figure S5 - Growth curve of *C. difficile* 630 Δ erm wild-type (WT) and $\Delta\Delta\Delta/dt$ strains in presence of sub-MIC of β -lactam antibiotics. Means and SD are shown; $n = 3$ independent experiments.




Figure S6 - Impact of the cephalosporin ceftriaxone and the carbapenem imipenem on the PG structure of vegetative cells of *C. difficile* $\Delta\Delta\Delta$ dt.

(A) LC-MS chromatograms of muropeptides from vegetative cells of *C. difficile* $\Delta\Delta\Delta$ dt strain grown in the presence of subinhibitory concentrations of ceftriaxone or imipenem. See also Table S1 for the structure of all identified muropeptides. Data are from one experiment.

(B) Abundance of muropeptides with a tetrapeptide or a pentapeptide stem and cross-linking index in the PG of *C. difficile* $\Delta\Delta\Delta$ dt strain grown in absence of antibiotics (no ATB) or in presence of ceftriaxone (ceftri.) or imipenem (imip). $n = 1$ experiment.

(C) Abundance of muropeptide dimers with a 3→3 crosslink relative to the total crosslinks in dimers in the PG of *C. difficile* $\Delta\Delta\Delta$ dt strain grown in the absence of antibiotics (no ATB) or in the presence of ceftriaxone (ceftri.) or imipenem (imip). $n = 1$ experiment.




Figure S7: Impact of the cephalosporin cefoxitin and the carbapenem meropenem on the PG structure of vegetative cells of *C. difficile* 630 Δ erm wild-type (WT).

(A) LC-MS chromatograms of muropeptides from vegetative cells of *C. difficile* WT strain grown in the presence of subinhibitory concentrations of cefoxitin or meropenem. See also Table S1 for the structure of all identified muropeptides. Data are representative of two independent experiments.

(B) Abundance of muropeptides with a tetrapeptide or a pentapeptide stem and cross-linking index in the PG of *C. difficile* WT strain grown in the absence of antibiotics (no ATB) or in the presence of cefoxitin (cefox.) or meropenem (merop).

(C) Abundance of muropeptide dimers with a 3→3 crosslink relative to the total crosslinks in dimers in the PG of *C. difficile* WT strain grown in the absence of antibiotics (no ATB) or in the presence of cefoxitin (cefox.) or meropenem (merop).

(D) Abundance of muropeptides with a pentapeptide stem ending with a non-canonical D-amino-acid (NCDAAs: Gly, Phe, Leu or Val) relative to the total pentapeptide muropeptides in the WT strain.

All graphs represent mean \pm SD and include individual data points; $n = 2$ independent experiments. *** $P \leq 0.001$ and **** $P \leq 0.001$ by a two-way ANOVA followed by a Dunnett's multiple comparisons test (B and C).